logo-loader
viewNaturally Splendid Enterprises Ltd.

Full interview: Naturally Splendid gets guidance from Health Canada as Biologic begins Phase 2 clinical trial

Naturally Splendid (CVE: NSP- OTC: NSPDF) partner Biologic Pharmamedical CEO Franco Cavaleri joined Steve Darling from Proactive Vancouver with news the company has received word back from Health Canada that the Biologics division will be one of the divisions of Health Canada handling this study.

Cavaleri also told Proactive, the trial will begin as a Phase 2 study and after an interim analysis is performed on the first 40 patients, the data will determine the number of expected patients needed to reach statistical significance in a Phase 3 study.

Quick facts: Naturally Splendid Enterprises Ltd.

Price: 0.05 CAD

TSX-V:NSP
Market: TSX-V
Market Cap: $9.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Naturally Splendid releases 2019 financial numbers including a rise in revenue

Naturally Splendid (CVE: NSP- OTC: NSPDF) CEO Craig Goodwin joined Steve Darling from Proactive Vancouver with news the company saw a nice increase in revenue in 2019 as the company released their full-year numbers. Goodwin discusses those numbers and also how the changes they made last year,...

2 weeks, 4 days ago

2 min read